Streetbeat News

Price Targets

ACM

IR

TDG

TGH

Four industrial stocks with high RSI values, indicating potential overbought conditions, may face a downturn in Q4. TransDigm Group (TDG) acquired a business for $1.385 billion and reported strong Q4 results. Ingersoll Rand (IR) raised full-year guidance despite lower sales. Textainer Group (TGH) showed resilience in Q3 results despite weak earnings. AECOM (ACM) exceeded earnings guidance and provided strong FY24 EPS guidance. All stocks are near their 52-week highs.

Portfolio Pulse from Lisa Levin

November 20, 2023 | 1:43 pm

KBH

Wedbush analyst Jay McCanless has downgraded KB Home (NYSE:KBH) from Outperform to Neutral and set a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:41 pm

SEDG

Morgan Stanley analyst Andrew Percoco has maintained an Equal-Weight rating on SolarEdge Technologies (NASDAQ:SEDG) but has reduced the price target from $176 to $89.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:40 pm

ENPH

Morgan Stanley analyst Andrew Percoco has maintained an Equal-Weight rating on Enphase Energy (NASDAQ:ENPH) but has reduced the price target from $135 to $94.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:37 pm

ADSK

Rosenblatt analyst Blair Abernethy has reiterated a Buy rating on Autodesk (NASDAQ:ADSK) and maintained a price target of $253.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:36 pm

CRWD

Morgan Stanley analyst Hamza Fodderwala has maintained an Equal-Weight rating on CrowdStrike Holdings (CRWD) and increased the price target from $175 to $187.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:34 pm

VTLE

Citigroup analyst Paul Diamond has initiated coverage on Vital Energy (NYSE:VTLE) with a Buy rating and set a price target of $60.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:32 pm

DCPH

JP Morgan analyst Jessica Fye has reinstated coverage on Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Neutral rating and set a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:17 pm

BCRX

JP Morgan analyst Jessica Fye has reinstated BioCryst Pharma (NASDAQ:BCRX) with an Overweight rating and set a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:15 pm

MIRM

JP Morgan analyst Jessica Fye has reinstated Mirum Pharmaceuticals (NASDAQ:MIRM) with an Overweight rating and set a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:14 pm